SlideShare a Scribd company logo
1 of 25
Download to read offline
Chemical Alternatives
Assessments: Combining
Exposure, (Health) Effects
and Life Cycle Assessment
Ann Mason, American Chemistry Council
Erin Mulholland, thinkstep
Hans Plugge, 3E Company
Hazard Assessment in
Alternatives Assessment
Ann M. Mason
American Chemistry Council
Moving from Hazard Assessment
to Risk Assessment in
Alternatives Assessment
Hans Plugge
3E Company
Hazard vs Risk
Hazard Assessment – the inherent hazard of a chemical via
specific or all routes of exposure without consideration of
exposure
Exposure Assessment – the likely amount of chemical
exposure to occur from a specific usage scenario for a
chemical/product
Risk Assessment – the probability of an effect resulting from
a particular chemical exposure scenario – for a single
chemical and scenario, the product of exposure and hazard
Hazard Assessment: Health Effects
List scores
Classification scores
Scientific data scores
Probabilistic data
Exposure Assessment
• Hundreds of scenarios available
• One exposure scenario at a
time
• Most exposures involve
multiple scenarios
• Need a way to sum exposure
Modeling
Spray Finishing
Activity
Chemical
h/day
Quantity Temp Room PPE
Product Liters °C Volume Value
Transport A, B, C 0.5 3.8 25 140 1
Mixing A, B 1.5 2 25 140 10
Spraying B 3 1.3 25 800 20
Flashing B 0.5 0.5 25 800 20
Cleaning C 1 1 25 140 10
Drying B 1.5 0.2 25 800 20
Exposure Assessment
Detailed analysis of scenarios
•May need multiple algorithms Population average vs high exposure
Need lots of physical chemistry data
Detailed chemical analysis of mixtures
Difficult to automate
Time-weighted average vs peak exposure
• Exposures modeled to be exceeding e.g. TWA need to be field verified
Exposure Screening
Single model for each scenario
Auto-selection of algorithms
Easy to obtain effect data
Auto-calculation of exposure and risk
Time-weighted summation of
exposures and hence risk
• Inherently simple
• Relative vs absolute risk
• Screening vs Regulatory Limits
• Occupational vs consumer
• Average vs sensitive vs high
exposure population
Risk Assessment
Potentials for Informing Exposure
Assessment through Life Cycle
Assessment
Erin Mulholland
thinkstep
Putting It All together: Integrating
Effects, Exposure and Life Cycle
Assessment
Hans Plugge
3E Company
Alternatives Assessment
Alternatives
Assessment is the
growing and rapidly
expanding art and
science of
evaluating the
relative hazards and
risks of existing
chemicals (or
products).
Informs the
scientific process of
substituting
functionally similar
chemicals with
reduced overall
health &
environmental risks.
Maintaining
functionality is of
utmost importance
– substitution must
provide similar
functionality within
a mixture (product)
or inherently makes
for an unacceptable
substitute.
Alternatives Assessment
• List based
• Classification based
• Scientific data based
Hazard
Assessment
• Screening
• Detailed
Exposure
Assessment
• Screening
• Detailed
Risk Assessment
Integrated Life
Cycle Assessment
WORSE
PRODUCT
COMPO-
SITION
CHEMICALS
OF
CONCERN
CHEMICAL
FUNCTIONALITY
EXISTING
ALTERNATIVES
R&D
DE NOVO
CHEMICALS
STRUCTURES
PHYSICAL
CHEMISTRY
CLASSICAL
IN VIVO
TOXICOLOGY
IN VITRO
ADVERSE
OUTCOME
PATHWAYS
ENZYME
DATA
TOXICOGENOMICS
DATA
ANALY-
TICS
DATA
GAPS
READ-ACROSS/ QSAR / MOLECULAR TOXICOLOGY
PRELIMINARY SCREENING HAZARD ASSESSMENT
(REGULATORY) HAZARD
ASSESSMENT
PHYSICAL
CHEMISTRY
EXPOSURE
ASSESSMENT
TOXICOLOGY
DATA
ECOTOXICOLOGY
DATA
(REGULATORY) RISK ASSESSMENT
REGULATORY ANALYSIS
INTERIM
LIFE
CYCLE
ASSESSMENT
SUSTAINABILITY ECONOMICS
ENGINEERING
PERFORMANCE
REGULATORY
ANALYSIS
ACCEPT
DOCUMENT
IMPLEMENT
FRAMEWORK FOR
ASSESSMENT OF CHEMICALS
GREEN CHEMISTRY AND ENGINEERING CONFERENCE
JUNE 14-16, 2016, PORTLAND, OR, USA
Hans Plugge & Longzhu Shen
3E Company & Yale University
Bethesda, MD & New Haven, CT
hplugge@3ecompany.com & longzhu.shen@yale.edu
After National Academy of Sciences, 2014
COMPUTATIONAL
CHEMISTRY
CHEMINFORMATICS
PROBABILISTIC
MODEL
WORSE
BETTER/EQUIVOCAL
BETTER/EQUIVOCAL
YES
NO
NO
YES
NO
Preliminary Screening
Data Gaps
Read Across
• Homologues e.g.
octanal vs heptanal
• Analogues e.g.
octanal vs
octanone
QSAR Quantitative
Structure Activity
Relationships
• Based on existing
(classical) data
Molecular Toxicology
• Based on
enzyme/in vitro
data
Screening Alternatives Assessment
Best outcome: greener Alternatives
No alternative better
Decreased exposure/risk?
Back to R&D
Regulatory Risk Assessment
Sustainability Assessment
Sustainability
Economics
Life Cycle Assessment
Engineering Performance
Regulatory Analysis
WORSE
PRODUCT
COMPO-
SITION
CHEMICALS
OF
CONCERN
CHEMICAL
FUNCTIONALITY
EXISTING
ALTERNATIVES
R&D
DE NOVO
CHEMICALS
STRUCTURES
PHYSICAL
CHEMISTRY
CLASSICAL
IN VIVO
TOXICOLOGY
IN VITRO
ADVERSE
OUTCOME
PATHWAYS
ENZYME
DATA
TOXICOGENOMICS
DATA
ANALY-
TICS
DATA
GAPS
READ-ACROSS/ QSAR / MOLECULAR TOXICOLOGY
PRELIMINARY SCREENING HAZARD ASSESSMENT
(REGULATORY) HAZARD
ASSESSMENT
PHYSICAL
CHEMISTRY
EXPOSURE
ASSESSMENT
TOXICOLOGY
DATA
ECOTOXICOLOGY
DATA
(REGULATORY) RISK ASSESSMENT
REGULATORY ANALYSIS
INTERIM
LIFE
CYCLE
ASSESSMENT
SUSTAINABILITY ECONOMICS
ENGINEERING
PERFORMANCE
REGULATORY
ANALYSIS
ACCEPT
DOCUMENT
IMPLEMENT
FRAMEWORK FOR
ASSESSMENT OF CHEMICALS
GREEN CHEMISTRY AND ENGINEERING CONFERENCE
JUNE 14-16, 2016, PORTLAND, OR, USA
Hans Plugge & Longzhu Shen
3E Company & Yale University
Bethesda, MD & New Haven, CT
hplugge@3ecompany.com & longzhu.shen@yale.edu
After National Academy of Sciences, 2014
COMPUTATIONAL
CHEMISTRY
CHEMINFORMATICS
PROBABILISTIC
MODEL
WORSE
BETTER/EQUIVOCAL
BETTER/EQUIVOCAL
YES
NO
NO
YES
NO
Uses of Alternatives Assessment
Greener products
More acceptable
across supply
chain
Consumer vs
industrial
Ranking of existing
products/releases
Prioritize R&D
New products
Up front analysis
of greenness
Incorporate
sustainability into
supply chain
Future
Alternatives Assessment is a
long term interim solution for
selecting greener chemicals.
Increasingly de novo green
chemistry will be used to
influence the selection of
greener chemicals eventually
taking over the entire process
of selecting greener chemicals
Eventually we will achieve the
Holy Grail: integrating risk
assessment and LCA in a semi-
automated screening approach
Authors
• Ann Mason
American Chemistry Council, Washington, DC
Ann_Mason@americanchemistry.com
• Erin Mulholland
thinkstep, Boston, MA
erin.mulholland@thinkstep.com
• Hans Plugge
3E Company, Bethesda, MD
hplugge@3ecompany.com

More Related Content

What's hot

How predictive models help Medicinal Chemists design better drugs_webinar
How predictive models help Medicinal Chemists design better drugs_webinarHow predictive models help Medicinal Chemists design better drugs_webinar
How predictive models help Medicinal Chemists design better drugs_webinar
Ann-Marie Roche
 

What's hot (17)

Measuring the Economic Value of Chemicals on Ecological System and Human Heal...
Measuring the Economic Value of Chemicals on Ecological System and Human Heal...Measuring the Economic Value of Chemicals on Ecological System and Human Heal...
Measuring the Economic Value of Chemicals on Ecological System and Human Heal...
 
Systematic Review Workflows and Semantic Solutions for Integrating Biological...
Systematic Review Workflows and Semantic Solutions for Integrating Biological...Systematic Review Workflows and Semantic Solutions for Integrating Biological...
Systematic Review Workflows and Semantic Solutions for Integrating Biological...
 
Reporting the Review Quiz
Reporting the Review QuizReporting the Review Quiz
Reporting the Review Quiz
 
Network meta analysis
Network meta analysisNetwork meta analysis
Network meta analysis
 
Re-analysis of the Cochrane Library data and heterogeneity challenges
Re-analysis of the Cochrane Library data and heterogeneity challengesRe-analysis of the Cochrane Library data and heterogeneity challenges
Re-analysis of the Cochrane Library data and heterogeneity challenges
 
Parameter Optimization of Shot Peening Process of PMG AL2024 Alloy Cover
Parameter Optimization of Shot Peening Process of PMG AL2024 Alloy CoverParameter Optimization of Shot Peening Process of PMG AL2024 Alloy Cover
Parameter Optimization of Shot Peening Process of PMG AL2024 Alloy Cover
 
Benefits-Costs Analysis: Triumphs and Troubles
Benefits-Costs Analysis: Triumphs and TroublesBenefits-Costs Analysis: Triumphs and Troubles
Benefits-Costs Analysis: Triumphs and Troubles
 
Network meta-analysis & models for inconsistency
Network meta-analysis & models for inconsistencyNetwork meta-analysis & models for inconsistency
Network meta-analysis & models for inconsistency
 
Analytical instrumentation 2015 contents
Analytical instrumentation 2015 contentsAnalytical instrumentation 2015 contents
Analytical instrumentation 2015 contents
 
Harmonization of Laboratory Testing, 08 04-2017
Harmonization of Laboratory Testing, 08 04-2017Harmonization of Laboratory Testing, 08 04-2017
Harmonization of Laboratory Testing, 08 04-2017
 
Open Journal of Chemistry
Open Journal of ChemistryOpen Journal of Chemistry
Open Journal of Chemistry
 
Adaptive Clinical Trials: Role of Modelling and Simulation
Adaptive Clinical Trials: Role of Modelling and Simulation Adaptive Clinical Trials: Role of Modelling and Simulation
Adaptive Clinical Trials: Role of Modelling and Simulation
 
Unit 1.1 language of analytical chemistry
Unit 1.1 language of analytical chemistryUnit 1.1 language of analytical chemistry
Unit 1.1 language of analytical chemistry
 
Non-inferiority and Equivalence Study design considerations and sample size
Non-inferiority and Equivalence Study design considerations and sample sizeNon-inferiority and Equivalence Study design considerations and sample size
Non-inferiority and Equivalence Study design considerations and sample size
 
Biostatistics II
Biostatistics IIBiostatistics II
Biostatistics II
 
How predictive models help Medicinal Chemists design better drugs_webinar
How predictive models help Medicinal Chemists design better drugs_webinarHow predictive models help Medicinal Chemists design better drugs_webinar
How predictive models help Medicinal Chemists design better drugs_webinar
 
Sample size for phase ii clinical trials-Simons design and mcp mod case studies
Sample size for phase ii clinical trials-Simons design and mcp mod case studies Sample size for phase ii clinical trials-Simons design and mcp mod case studies
Sample size for phase ii clinical trials-Simons design and mcp mod case studies
 

Similar to Chemical Alternatives Assessments_HP

bio equivalence studies
bio equivalence studiesbio equivalence studies
bio equivalence studies
RamyaP53
 
Epidemiologic study designs_COM 202_FAKUNLE.pptx
Epidemiologic study designs_COM 202_FAKUNLE.pptxEpidemiologic study designs_COM 202_FAKUNLE.pptx
Epidemiologic study designs_COM 202_FAKUNLE.pptx
AkinsolaAyomidotun
 

Similar to Chemical Alternatives Assessments_HP (20)

Weighing evidence of biological relevance: from empirical testing in rats to ...
Weighing evidence of biological relevance: from empirical testing in rats to ...Weighing evidence of biological relevance: from empirical testing in rats to ...
Weighing evidence of biological relevance: from empirical testing in rats to ...
 
Drug Discovery & Development Overview
Drug Discovery & Development OverviewDrug Discovery & Development Overview
Drug Discovery & Development Overview
 
Crofton Evolution of Toxicology
Crofton Evolution of ToxicologyCrofton Evolution of Toxicology
Crofton Evolution of Toxicology
 
Exposure Assessment, George Gray
Exposure Assessment, George GrayExposure Assessment, George Gray
Exposure Assessment, George Gray
 
Risk Assessment and RIA, George Gray
Risk Assessment and RIA, George GrayRisk Assessment and RIA, George Gray
Risk Assessment and RIA, George Gray
 
Tox_Testing.ppt
Tox_Testing.pptTox_Testing.ppt
Tox_Testing.ppt
 
Evaluating the chemicals in your products comparing and contrasting leading ...
Evaluating the chemicals in your products  comparing and contrasting leading ...Evaluating the chemicals in your products  comparing and contrasting leading ...
Evaluating the chemicals in your products comparing and contrasting leading ...
 
Methods used to assure high quality study for ERA
Methods used to assure high quality study for ERAMethods used to assure high quality study for ERA
Methods used to assure high quality study for ERA
 
The Continuous Update Project: Novel approach to reviewing mechanistic evide...
 The Continuous Update Project: Novel approach to reviewing mechanistic evide... The Continuous Update Project: Novel approach to reviewing mechanistic evide...
The Continuous Update Project: Novel approach to reviewing mechanistic evide...
 
bio equivalence studies
bio equivalence studiesbio equivalence studies
bio equivalence studies
 
Comparing research designs fw 2013 handout version
Comparing research designs fw 2013 handout versionComparing research designs fw 2013 handout version
Comparing research designs fw 2013 handout version
 
Epidemiology: a bird’s eye view
Epidemiology: a bird’s eye viewEpidemiology: a bird’s eye view
Epidemiology: a bird’s eye view
 
Mey Akashah "Risk Assessment," Harvard
Mey Akashah "Risk Assessment," HarvardMey Akashah "Risk Assessment," Harvard
Mey Akashah "Risk Assessment," Harvard
 
BA-BE Bio-availability and Bio-equivalency
BA-BE Bio-availability and Bio-equivalencyBA-BE Bio-availability and Bio-equivalency
BA-BE Bio-availability and Bio-equivalency
 
Bioassay
BioassayBioassay
Bioassay
 
Epidemiologic study designs_COM 202_FAKUNLE.pptx
Epidemiologic study designs_COM 202_FAKUNLE.pptxEpidemiologic study designs_COM 202_FAKUNLE.pptx
Epidemiologic study designs_COM 202_FAKUNLE.pptx
 
5. IOHA - biomarkers and the internal exposome
5. IOHA - biomarkers and the internal exposome5. IOHA - biomarkers and the internal exposome
5. IOHA - biomarkers and the internal exposome
 
BaBE-Bioavailability and Bioequivalance
BaBE-Bioavailability and BioequivalanceBaBE-Bioavailability and Bioequivalance
BaBE-Bioavailability and Bioequivalance
 
Phase I trials - Educational course at the PAMM-2019 winter meeting
Phase I trials - Educational course at the PAMM-2019 winter meetingPhase I trials - Educational course at the PAMM-2019 winter meeting
Phase I trials - Educational course at the PAMM-2019 winter meeting
 
Toxicological Risk Assessment For Medical Devices - ISO 10993-1
Toxicological Risk Assessment For Medical Devices - ISO 10993-1Toxicological Risk Assessment For Medical Devices - ISO 10993-1
Toxicological Risk Assessment For Medical Devices - ISO 10993-1
 

Chemical Alternatives Assessments_HP

  • 1. Chemical Alternatives Assessments: Combining Exposure, (Health) Effects and Life Cycle Assessment Ann Mason, American Chemistry Council Erin Mulholland, thinkstep Hans Plugge, 3E Company
  • 2. Hazard Assessment in Alternatives Assessment Ann M. Mason American Chemistry Council
  • 3. Moving from Hazard Assessment to Risk Assessment in Alternatives Assessment Hans Plugge 3E Company
  • 4. Hazard vs Risk Hazard Assessment – the inherent hazard of a chemical via specific or all routes of exposure without consideration of exposure Exposure Assessment – the likely amount of chemical exposure to occur from a specific usage scenario for a chemical/product Risk Assessment – the probability of an effect resulting from a particular chemical exposure scenario – for a single chemical and scenario, the product of exposure and hazard
  • 5. Hazard Assessment: Health Effects List scores Classification scores Scientific data scores Probabilistic data
  • 6. Exposure Assessment • Hundreds of scenarios available • One exposure scenario at a time • Most exposures involve multiple scenarios • Need a way to sum exposure Modeling
  • 7. Spray Finishing Activity Chemical h/day Quantity Temp Room PPE Product Liters °C Volume Value Transport A, B, C 0.5 3.8 25 140 1 Mixing A, B 1.5 2 25 140 10 Spraying B 3 1.3 25 800 20 Flashing B 0.5 0.5 25 800 20 Cleaning C 1 1 25 140 10 Drying B 1.5 0.2 25 800 20
  • 8. Exposure Assessment Detailed analysis of scenarios •May need multiple algorithms Population average vs high exposure Need lots of physical chemistry data Detailed chemical analysis of mixtures Difficult to automate Time-weighted average vs peak exposure • Exposures modeled to be exceeding e.g. TWA need to be field verified
  • 9. Exposure Screening Single model for each scenario Auto-selection of algorithms Easy to obtain effect data Auto-calculation of exposure and risk Time-weighted summation of exposures and hence risk
  • 10. • Inherently simple • Relative vs absolute risk • Screening vs Regulatory Limits • Occupational vs consumer • Average vs sensitive vs high exposure population Risk Assessment
  • 11. Potentials for Informing Exposure Assessment through Life Cycle Assessment Erin Mulholland thinkstep
  • 12. Putting It All together: Integrating Effects, Exposure and Life Cycle Assessment Hans Plugge 3E Company
  • 13. Alternatives Assessment Alternatives Assessment is the growing and rapidly expanding art and science of evaluating the relative hazards and risks of existing chemicals (or products). Informs the scientific process of substituting functionally similar chemicals with reduced overall health & environmental risks. Maintaining functionality is of utmost importance – substitution must provide similar functionality within a mixture (product) or inherently makes for an unacceptable substitute.
  • 14. Alternatives Assessment • List based • Classification based • Scientific data based Hazard Assessment • Screening • Detailed Exposure Assessment • Screening • Detailed Risk Assessment Integrated Life Cycle Assessment
  • 15. WORSE PRODUCT COMPO- SITION CHEMICALS OF CONCERN CHEMICAL FUNCTIONALITY EXISTING ALTERNATIVES R&D DE NOVO CHEMICALS STRUCTURES PHYSICAL CHEMISTRY CLASSICAL IN VIVO TOXICOLOGY IN VITRO ADVERSE OUTCOME PATHWAYS ENZYME DATA TOXICOGENOMICS DATA ANALY- TICS DATA GAPS READ-ACROSS/ QSAR / MOLECULAR TOXICOLOGY PRELIMINARY SCREENING HAZARD ASSESSMENT (REGULATORY) HAZARD ASSESSMENT PHYSICAL CHEMISTRY EXPOSURE ASSESSMENT TOXICOLOGY DATA ECOTOXICOLOGY DATA (REGULATORY) RISK ASSESSMENT REGULATORY ANALYSIS INTERIM LIFE CYCLE ASSESSMENT SUSTAINABILITY ECONOMICS ENGINEERING PERFORMANCE REGULATORY ANALYSIS ACCEPT DOCUMENT IMPLEMENT FRAMEWORK FOR ASSESSMENT OF CHEMICALS GREEN CHEMISTRY AND ENGINEERING CONFERENCE JUNE 14-16, 2016, PORTLAND, OR, USA Hans Plugge & Longzhu Shen 3E Company & Yale University Bethesda, MD & New Haven, CT hplugge@3ecompany.com & longzhu.shen@yale.edu After National Academy of Sciences, 2014 COMPUTATIONAL CHEMISTRY CHEMINFORMATICS PROBABILISTIC MODEL WORSE BETTER/EQUIVOCAL BETTER/EQUIVOCAL YES NO NO YES NO
  • 17. Data Gaps Read Across • Homologues e.g. octanal vs heptanal • Analogues e.g. octanal vs octanone QSAR Quantitative Structure Activity Relationships • Based on existing (classical) data Molecular Toxicology • Based on enzyme/in vitro data
  • 18. Screening Alternatives Assessment Best outcome: greener Alternatives No alternative better Decreased exposure/risk? Back to R&D
  • 22. WORSE PRODUCT COMPO- SITION CHEMICALS OF CONCERN CHEMICAL FUNCTIONALITY EXISTING ALTERNATIVES R&D DE NOVO CHEMICALS STRUCTURES PHYSICAL CHEMISTRY CLASSICAL IN VIVO TOXICOLOGY IN VITRO ADVERSE OUTCOME PATHWAYS ENZYME DATA TOXICOGENOMICS DATA ANALY- TICS DATA GAPS READ-ACROSS/ QSAR / MOLECULAR TOXICOLOGY PRELIMINARY SCREENING HAZARD ASSESSMENT (REGULATORY) HAZARD ASSESSMENT PHYSICAL CHEMISTRY EXPOSURE ASSESSMENT TOXICOLOGY DATA ECOTOXICOLOGY DATA (REGULATORY) RISK ASSESSMENT REGULATORY ANALYSIS INTERIM LIFE CYCLE ASSESSMENT SUSTAINABILITY ECONOMICS ENGINEERING PERFORMANCE REGULATORY ANALYSIS ACCEPT DOCUMENT IMPLEMENT FRAMEWORK FOR ASSESSMENT OF CHEMICALS GREEN CHEMISTRY AND ENGINEERING CONFERENCE JUNE 14-16, 2016, PORTLAND, OR, USA Hans Plugge & Longzhu Shen 3E Company & Yale University Bethesda, MD & New Haven, CT hplugge@3ecompany.com & longzhu.shen@yale.edu After National Academy of Sciences, 2014 COMPUTATIONAL CHEMISTRY CHEMINFORMATICS PROBABILISTIC MODEL WORSE BETTER/EQUIVOCAL BETTER/EQUIVOCAL YES NO NO YES NO
  • 23. Uses of Alternatives Assessment Greener products More acceptable across supply chain Consumer vs industrial Ranking of existing products/releases Prioritize R&D New products Up front analysis of greenness Incorporate sustainability into supply chain
  • 24. Future Alternatives Assessment is a long term interim solution for selecting greener chemicals. Increasingly de novo green chemistry will be used to influence the selection of greener chemicals eventually taking over the entire process of selecting greener chemicals Eventually we will achieve the Holy Grail: integrating risk assessment and LCA in a semi- automated screening approach
  • 25. Authors • Ann Mason American Chemistry Council, Washington, DC Ann_Mason@americanchemistry.com • Erin Mulholland thinkstep, Boston, MA erin.mulholland@thinkstep.com • Hans Plugge 3E Company, Bethesda, MD hplugge@3ecompany.com